NCT06625372 Comparison of Intralipid With SMOF Lipid Following HSCT
| NCT ID | NCT06625372 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shahid Beheshti University |
| Condition | Leukemia |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-10-12 |
| Primary Completion | 2025-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2024-10-12 with a primary completion date of 2025-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to have a successful engraftment in after bone transplantation. Acute leukemia patient of both sexes aged 2 to 18 years, who are transplant candidates, participate in this study. Primary hypothesis is Patients receiving SMOF LIPID will have better grafts than patients receiving intralipid. Also, complications after surgery and malnutrition will be less in this group.
Eligibility Criteria
Inclusion Criteria: * Willingness to cooperate and complete the informed consent form by the legal guardian of the child; * Age ≤ 18 years; * Definitive diagnosis of acute leukemia and candidate for hematopoietic stem ● cell transplantation; * Eligible for parenteral nutrition support; * No contraindications for parenteral nutrition; * No history of allergy to egg or soy protein; * Absence of severe organ failure or impaired liver function test (bilirubin \> 2.5 mg/dL). Exclusion Criteria: * Death of the child earlier than 5 days from the start of the intervention; * Unwillingness to continue cooperation during study; * Occurrence of side effects during the study; * In case of sepsis, hypotension, shock, thrombosis, myocardial infarction, liver dysfunction, the patient will be excluded from the study.
Contact & Investigator
Zahra Vahdat Shariatpanahi, Professor
PRINCIPAL INVESTIGATOR
School of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences
Frequently Asked Questions
Who can join the NCT06625372 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, up to 18 Years, studying Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06625372 currently recruiting?
Yes, NCT06625372 is actively recruiting participants. Contact the research team at nutritiondata@yahoo.com for enrollment information.
Where is the NCT06625372 trial being conducted?
This trial is being conducted at Tehran, Iran.
Who is sponsoring the NCT06625372 clinical trial?
NCT06625372 is sponsored by Shahid Beheshti University. The principal investigator is Zahra Vahdat Shariatpanahi, Professor at School of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.